ORKA News and Press, Oruka Therapeutics Inc. From 11/12/25

ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three key readouts: ORKA-001 Phase 2a and 2b (EVERLAST-A and -B), and ORKA-002 Phase 2 ...

RWE AG ADR (RWEOY) is expected to report $0.16 for Q3 2025 Hillenbrand Inc (HI) is expected to report $0.62 for Q4 2025 Ardent Health Inc. (ARDT) is expected to report $0.42 for Q3 2025 Quince Therapeutics Inc. (QNCX) is expected to report $-0.2 for Q3 2025 GlobalFoundries Inc. (G...

2025-10-27 08:15:14 ET H.C. Wainwright analyst issues BUY recommendation for ORKA on October 27, 2025 10:20AM ET. The previous analyst recommendation was Buy. ORKA was trading at $27.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curr...

2025-10-03 17:27:55 ET More on Oruka Therapeutics Oruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trial Seeking Alpha’s Quant Rating on Oruka Therapeutics Historical earnings data for Oruka Therapeutics Financial information...

2025-09-30 13:34:03 ET More on MoonLake Immunotherapeutics MoonLake: From 'Best-In-Class' Hopes To Approvability Debate (Rating Downgrade) MoonLake Immunotherapeutics (MLTX) RND Day Conference Call (Transcript) MoonLake Immunotherapeutics (MLTX) RND Day Conference Pr...

2025-09-17 08:46:48 ET More on Oruka Therapeutics, AbbVie AbbVie: Best Time To Sell In 5 Years (Rating Downgrade) AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) AbbVie Smashes Earnings, Bets Big On Depression Drug ...

MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque pso...

Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-treatment remissions Well tolerated with a favorable safety profile consistent wit...

2025-08-11 16:30:58 ET More on Oruka Therapeutics Historical earnings data for Oruka Therapeutics Financial information for Oruka Therapeutics Read the full article on Seeking Alpha For further details see: Oruka Therapeutics GAAP EPS of -$0.46 beats by $...

First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025 MENLO PARK, Calif...